

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Alzheimer's disease (AD)	Histone deacetylase 6 (HDAC6)	<p><i>In vitro</i> and mouse studies identified HDAC6 inhibitors that could help treat AD. In human neuronal cells, hydroxamic acid-based quinazoline-4-one derivatives that specifically inhibited HDAC6 induced neurite outgrowth and synaptic activity. In mice with hippocampal <math>\beta</math>-amyloid (A<math>\beta</math>) aggregation, intraperitoneal injection of either of two different inhibitors decreased learning impairments compared with vehicle injection. Ongoing studies include lead optimization of the inhibitor series.</p> <p>Acetylon Pharmaceuticals Inc. has the HDAC6 inhibitor ACY-1215 in Phase I/II testing to treat multiple myeloma (MM).</p> <p>At least two other companies have HDAC6 inhibitors in preclinical development to treat cancer and inflammation.</p> <p><b>SciBX 6(35); doi:10.1038/scibx.2013.967</b>  <b>Published online Sept. 12, 2013</b></p>	Patent application filed; licensed by AnnJi Pharmaceutical Co.; unavailable for licensing	Yu, C.-W. <i>et al. J. Med. Chem.</i> ; published online Aug. 1, 2013; doi:10.1021/jm400564j <b>Contact:</b> Ji-Wang Chern, National Taiwan University, Taipei, Taiwan e-mail: <a href="mailto:jwchern@ntu.edu.tw">jwchern@ntu.edu.tw</a>